Last reviewed · How we verify

NCT07175909

Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease

Recruiting now NA Last updated 16 September 2025
What this trial tests

NA trial testing The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology in Dry Eye Disease (DED) in 75 participants. Currently enrolling.

Timeline
1 January 2021
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorThe Hong Kong Polytechnic University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment75
Start date1 January 2021
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

The Hong Kong Polytechnic University

Who can join

Adults 18 to 65, any sex, with Dry Eye Disease (DED) or Dry Eye. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the initial tear proteome profiles in Dry Eye Disease (DED) patients, the safety and effectiveness of using an EC certificate DED treatment device in DED management, together with the associated global tear proteome changes, will be investigated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology

Trials testing the same drug.

Other recruiting trials for Dry Eye Disease (DED)

Currently open trials in the same condition.

Other The Hong Kong Polytechnic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07175909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing